- Stocks
- Pharma & Healthcare
- SUPHA PHARMACHE
SUPHA PHARMACHE share price
NSE: SUPHAPharma & HealthcareDrug Manufacturers - Specialty & Generic
SUPHA PHARMACHE at a glance
With a market capitalisation of ₹25 Cr, it ranks 3477th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 4.9% in FY25. In Q2 FY26, the quarter ended 30 Sep 2025, revenue was ₹111 Cr and net profit ₹9 Cr, on a consolidated basis. Promoters held 1.13% of the company as of 31 Dec 2025.
Key numbers
- Market cap
- ₹25 CrRank 3477 on NSE
- Price to book
- 1.67×FY25
- ROE
- 4.9%FY25
- ROCE
- 22.0%FY25
- Debt to equity
- 26.01FY25
- Net profit margin
- 0.5%FY25
- Book value / share
- ₹1.09FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
SUPHA PHARMACHE quarterly results
| Quarter | Q1 FY26 | Q2 FY26 |
|---|---|---|
| Revenue | ₹113 Cr | ₹111 Cr |
| Revenue YoY | — | — |
| Net profit | ₹5 Cr | ₹9 Cr |
| Net profit YoY | — | — |
| Net margin | 4.1% | 7.8% |
| EPS | ₹0.05 | ₹0.10 |
SUPHA PHARMACHE financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹3 Cr | ₹90 Cr | ₹505 Cr | ₹510 Cr | ₹4,042 Cr | ₹223 Cr |
| Operating profit | ₹0 Cr | ₹1 Cr | ₹2 Cr | ₹7 Cr | ₹50 Cr | ₹4 Cr |
| Net profit | ₹0 Cr | ₹0 Cr | ₹1 Cr | ₹5 Cr | ₹33 Cr | ₹2 Cr |
| EPS (₹) | ₹0.77 | ₹1.33 | ₹2.99 | ₹15.07 | ₹3.25 | ₹0.04 |
| Cash from operations | −₹0 Cr | −₹10 Cr | ₹11 Cr | ₹21 Cr | −₹74 Cr | ₹0 Cr |
| Total debt | — | — | — | — | — | ₹0 Cr |
| Shareholders' equity | — | — | — | — | — | ₹44 Cr |
SUPHA PHARMACHE shareholding pattern
| Holder | 30 Sep 2024 | 31 Dec 2024 | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 |
|---|---|---|---|---|---|---|
| Promoters | 1.11% | 1.11% | 1.11% | 1.13% | 1.13% | 1.13% |
| Foreign institutions | — | — | — | — | — | 1.70% |
| Non-institutions | 98.89% | 98.89% | 98.89% | 98.87% | 98.87% | 97.17% |
SUPHA PHARMACHE vs peers
The listed Pharma & Healthcare companies nearest to SUPHA PHARMACHE by market capitalisation.
Ask anything about SUPHA PHARMACHE
Pivot answers on the live chart with evidence you can check, and tests strategies against SUPHA's own history. Try: “Why has SUPHA moved over the last three months?” · “Backtest a 50-day moving-average crossover on SUPHA over five years” · “Compare SUPHA with TEJNAKSH on margins and valuation”
Frequently asked questions about SUPHA PHARMACHE
What is the market cap of SUPHA PHARMACHE?
SUPHA PHARMACHE's market capitalisation is ₹25 Cr (₹25 Cr) at the 22 Oct 2026 close, ranking 3477th among the NSE companies Pivot tracks.
What is the ROE and ROCE of SUPHA PHARMACHE?
Return on equity was 4.9% in FY25 and return on capital employed was 22.0% in FY25 (consolidated figures).
Is SUPHA PHARMACHE a debt-free company?
No. SUPHA PHARMACHE's debt-to-equity ratio was 26.01 in FY25, with total debt of ₹0 Cr.
What were SUPHA PHARMACHE's latest quarterly results?
For Q2 FY26 (quarter ended 30 Sep 2025), SUPHA PHARMACHE reported revenue of ₹111 Cr and net profit of ₹9 Cr.
What is the shareholding pattern of SUPHA PHARMACHE?
As of 31 Dec 2025: promoters 1.13%, foreign institutions 1.70%, non-institutions 97.17%.
Who are SUPHA PHARMACHE's competitors?
The listed Pharma & Healthcare companies closest to SUPHA PHARMACHE by market cap are Tejnaksh, SAMSRITA LABS, Parmax Pharma, Transgene Biote, Hamps Bio and Rekvina Labs.
Is SUPHA PHARMACHE a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out SUPHA PHARMACHE's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on SUPHA against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with S · all NSE stocks · this page as text